Rheumatism News and Research

RSS

Rheumatism is a group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat.

Rheumatoid arthritis drug has added benefits

Treatment with anti-tumor necrosis factor drugs reduces the risk for cardiovascular events in patients with rheumatoid arthritis, researchers report.

8 Jun 2012

Smoking RA patients don't respond to anti-TNF drugs

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.

8 Jun 2012

Hypocaloric diet may help achieve minimal disease activity in psoriatic arthritis patients

According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet.

8 Jun 2012

Lung changes in association with ACPA status are a primary manifestation of RA

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that lung changes in association with anti-citrullinated protein autoantibody (ACPA) status are a primary manifestation of rheumatoid arthritis (RA).

8 Jun 2012

Data from abatacept versus adalimumab Phase IIIb comparison study on RA

Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20.

8 Jun 2012

Patients over 45 years with history of early menopause 50% less likely to develop severe RA

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA).

8 Jun 2012

Study calls for more aggressive management of osteoporosis in the extreme elderly

A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.

8 Jun 2012

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases

Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.

8 Jun 2012

Initial HSCT results from phase III trial on systemic sclerosis

Initial results from an international, investigator-initiated, open label phase III trial were presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism. Data indicate that haematopoietic stem cell transplantation (HSCT) results in better long term survival than conventional treatment for patients with poor prognosis early diffuse cutaneous systemic sclerosis.

7 Jun 2012

Biologic treatments reduce mortality risk in patients with rheumatoid arthritis

According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab).

7 Jun 2012

Savient announces results from KRYSTEXXA Phase III trials on gout-related kidney disease

Savient Pharmaceuticals, Inc. announced that new data presented in an oral session at the European League Against Rheumatism (EULAR) 2012 congress showed that patients with refractory chronic gout (RCG) who also suffer from chronic kidney disease (CKD) responded to treatment with KRYSTEXXA (pegloticase) regardless of baseline CKD stage.

7 Jun 2012

ADACTA trial: Tocilizumab more effective than adalimumab in treating RA

Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p<0.0001) at week 24.

7 Jun 2012

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, has identified five biomarkers that may predict the progression of structural damage in the spine of patients with Ankylosing Spondylitis (AS) who are already at high risk of disease progression.

7 Jun 2012

English Rheumatoid Arthritis care standards out of step with Europe

A 12-country comparative analysis of rheumatoid arthritis (RA) treatment guidelines reveals that there is considerable variation in patient access to care, with England out of step with standards adopted by its European counterparts.

6 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012

Special echocardiograms show promise for early detection of heart disease in RA patients

Special echocardiograms show promise for early detection of a potentially deadly complication in rheumatoid arthritis: heart disease, Mayo Clinic research shows. The findings were being presented at The European League Against Rheumatism annual meeting in Berlin.

6 Jun 2012

Functional disability impacts educational attainment in children with JIA

As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood.

1 Jun 2012

Juvenile Arthritis patients may have difficulties achieving educational success

31 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

Rheumatism News and Research

Further Reading

Rheumatoid arthritis drug has added benefits

Smoking RA patients don't respond to anti-TNF drugs

Hypocaloric diet may help achieve minimal disease activity in psoriatic arthritis patients

Lung changes in association with ACPA status are a primary manifestation of RA

Data from abatacept versus adalimumab Phase IIIb comparison study on RA

Patients over 45 years with history of early menopause 50% less likely to develop severe RA

Study calls for more aggressive management of osteoporosis in the extreme elderly

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases

Initial HSCT results from phase III trial on systemic sclerosis

Biologic treatments reduce mortality risk in patients with rheumatoid arthritis

Savient announces results from KRYSTEXXA Phase III trials on gout-related kidney disease

ADACTA trial: Tocilizumab more effective than adalimumab in treating RA

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

English Rheumatoid Arthritis care standards out of step with Europe

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Abbott announces results from HUMIRA Phase 3 study on axSpA

Special echocardiograms show promise for early detection of heart disease in RA patients

Functional disability impacts educational attainment in children with JIA

Juvenile Arthritis patients may have difficulties achieving educational success

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Improving healthcare sustainability through carbon data

Latest News